{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:52:03Z","timestamp":1784307123218,"version":"3.55.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>CAR-T therapy, an innovative immunotherapeutic approach, genetically modifies T cells to express CARs, enabling targeted destruction of specific antigen-expressing cells. Initially developed for oncology, CAR-T therapy has shown significant potential in treating autoimmune diseases. By targeting CD19+ B cells, CAR-T therapy has demonstrated rapid and sustained remission in refractory cases, with studies showing normalized laboratory parameters and reduced disease activity. At the same time, CAR-NK, CAAR-T and CAR-Treg technologies further broaden therapeutic strategies. However, some adverse effects also exist, including CRS, ICANS and so on. Despite these challenges, CAR therapy represents a promising advancement in autoimmune disease treatment, with ongoing research aimed at enhancing efficacy, durability, and safety. Continuous innovation is essential to address limitations and optimize therapeutic outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1625166","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:15:42Z","timestamp":1755058542000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuanhao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291x(87)90502-x","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"B2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus [published correction appears in Nat Med. 2023 Nov;29(11):2956. doi:\u00a010.1038\/s41591-022-02091-9","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2403743","article-title":"Anti-CD19 CAR T cells in refractory immune thrombocytopenia of SLE","volume":"391","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus [published correction appears in Arthritis Rheumatol. 2025 Jan 31. doi:\u00a010.1002\/art.43080","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2315990121","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e004727","DOI":"10.1136\/rmdopen-2024-004727","article-title":"Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel","volume":"10","author":"Szabo","year":"2024","journal-title":"RMD Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-024-01068-2","article-title":"Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis","author":"Li","year":"2025","journal-title":"Cell Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100676","article-title":"CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease","author":"Par\u00eds-Mu\u00f1oz","year":"2025","journal-title":"Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418768","article-title":"Incidentally cured psoriasis in a patient with refractory\/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1529745","article-title":"Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: a case report","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.10.5970","article-title":"Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus","volume":"165","author":"Odendahl","year":"2000","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity","author":"Mei","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100003","article-title":"Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells [published correction appears in Cell Rep Med. 2020 Aug 25;1(5):100080. doi:\u00a010.1016\/j.xcrm.2020.100080","volume":"1","author":"Reighard","year":"2020","journal-title":"Cell Rep Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1182\/blood-2023-186669","article-title":"CD19\/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus: safety and preliminary efficacy data from a phase I clinical study","volume":"142","author":"Feng","year":"2023","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1235222","article-title":"CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis","volume":"14","author":"Moorman","year":"2023","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1144414","article-title":"CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern","volume":"14","author":"Velasco","year":"2023","journal-title":"Front Neurol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40291-024-00730-0","article-title":"The future of CAR T therapeutics to treat autoimmune disorders","volume":"28","author":"Pecher","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12766","article-title":"Highlight of 2023: CAR T cells driving precision therapy for autoimmune disease","volume":"102","author":"Lee","year":"2024","journal-title":"Immunol Cell Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152479","article-title":"Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions","volume":"67","author":"Ohno","year":"2024","journal-title":"Semin Arthritis Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12032-024-02362-0","article-title":"A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases","volume":"41","author":"Hassan","year":"2024","journal-title":"Med Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3390\/biomedicines10071493","article-title":"Alternative CAR therapies: recent approaches in engineering chimeric antigen receptor immune cells to combat cancer","volume":"10","author":"Moreno","year":"2022","journal-title":"Biomedicines"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283874","article-title":"GPIba CAAR T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia","volume":"109","author":"Zhou","year":"2024","journal-title":"Haematologica"},{"key":"B49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1184937","article-title":"CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions","volume":"3","author":"Abraham","year":"2023","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103369","article-title":"CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy","volume":"151","author":"Uppin","year":"2025","journal-title":"J Autoimmun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14696","article-title":"CAR T-cells: New therapeutic opportunities in autoimmune diseases","volume":"26","author":"Chou","year":"2023","journal-title":"Int J Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1625166\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:15:43Z","timestamp":1755058543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1625166\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2025.1625166"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1625166","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1625166"}}